Glenmark's molecule for pain therapy entering human trials

Tags: Companies
Glenmark Pharmaceuticals today said its novel chemical entity for potential treatment of chronic inflammatory disorders is entering human trials.

Glenmark has completed preclinical studies and Phase 1 enabling good laboratory practise for the molecule, GRC 27864, and has filed a Phase 1 application for first-in-human trial with the MHRA, UK, Glenmark Pharma said in a BSE filing.

The Phase 1 studies are to be initiated soon and are likely to get completed by January 2015, it added.

Glenmark Pharmaceuticals Ltd Chief Scientific Officer Michael Buschle said: "This is another first-in-class molecule and there is a significant unmet medical need. This announcement also reaffirms our position globally in the development of novel pain therapies."

Indicating potential and size of the market for the drug, the firm said: " 20% of the global adult population suffers from pain with 10% of newly diagnosed cases of chronic pain cases being added every year."

Following human trial, Glenmark will initiate a proof of concept study in patients with acute pain.

EDITORIAL OF THE DAY

  • It’s time to shift sugarcane production to water abundant states of eastern India

    During the 10 years of UPA rule, the country was able to come out of the so-called sugar cycle — two years of surplus followed by two years of defic

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Simon J Evenett

VW scandal has lessons for Make in India

In recent years, when it comes to widespread corporate wrongdoing, ...

Zehra Naqvi

The flame of hate

Pyre. The name itself evokes a sense of foreboding, casting ...

Dharmendra Khandal

So, how do we define a 'vermin'?

These days there’s an ongoing debate whether to declare various ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture